Simultaneous Head and Neck and Lung Cancers: Implications and Therapeutic Management Timing
Clinical Otolaryngology · 2026
DOI: 10.1111/coa.70066 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Otolaryngology, 2026. Verfasst von Dario Ebode und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oto-Rhino-Laryngology Head and Neck Surgery, APHM, La Conception University Hospital, Aix-Marseille University, Marseille, France. Hauptthemen laut MEDLINE: Lung Neoplasms, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Time-to-Treatment. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
This study aims to describe the characteristics of patients with simultaneous head and neck squamous cell carcinomas (HNSCCs) and lung cancer and to assess the impact of diagnosis‐to‐treatment interval (DTI) and treatment choices on outcomes. Design and Setting A bicentric retrospective observational study conducted between 2003 and 2020 in two tertiary referral academic hospitals.
Participants
Forty‐three patients diagnosed with both HNSCC and lung cancer within 1 month were compared to a 1:2 control group of patients diagnosed with HNSCC alone. The groups were matched by tumour location, TNM stage and treatment centre. Multivariate analysis was used to assess factors influencing DTI, and survival analysis was conducted using the Kaplan–Meier estimator. Main Outcome Measures Primary outcomes included DTI and overall survival.
Results
Patients with simultaneous cancers were predominantly male (84%) with heavy smoking histories. Most HNSCC cases (84%) were diagnosed at advanced stages (III/IV), while lung cancers were predominantly early stage (I–II). Patients with simultaneous cancers had significantly longer DTIs (median 43 days, IQR [32.8–85.8]) compared to controls (28 days, IQR [19.0–38.0]) ( p < 0.001; HR = 0.35, p = 0.0001). As expected, overall survival was markedly worse for patients with simultaneous cancers (median 17.8 months, 95% CI [12.6–31.0]) versus controls (56.5 months, 95% CI [38.4–], p < 0.001).
Conclusion
Prolonged DTI may contribute to the poorer survival outcomes in patients with simultaneous cancers. Strategies to reduce delays, such as performing concurrent bronchoscopy and endoscopy, should be explored.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oto-Rhino-Laryngology Head and Neck Surgery, APHM, La Conception University Hospital, Aix-Marseille University, Marseille, France.
- Department of Otorhinolaryngology, Reims University Hospital, Reims, France.
- Department of Otorhinolaryngology, Bichat University Hospital, University of Paris, Paris, France.
- Clinical Research, Biostatistics and Epidemiology Department, AP-HP Nord-Université de Paris, HUPNVS, Paris Cedex, France.
- INSERM CIC-EC 1425, Hôpital Bichat Claude Bernard, Paris, France.
- Department of Thoracic Oncology, Bichat University Hospital, University of Paris, Paris, France.
ORCID-Profile: Dario Ebode, Esteban Brenet
Zitieren
APA
Ebode, D., Truong, F., Halimi, C., Dupont, A., Gounant, V., Faivre, S., Hourseau, M., Barry, B., Brenet, E., & Evrard, D. (2026). Simultaneous Head and Neck and Lung Cancers: Implications and Therapeutic Management Timing. Clinical Otolaryngology. https://doi.org/10.1111/coa.70066
Vancouver
Ebode D, Truong F, Halimi C, Dupont A, Gounant V, Faivre S, et al. Simultaneous Head and Neck and Lung Cancers: Implications and Therapeutic Management Timing. Clinical Otolaryngology. 2026. doi:10.1111/coa.70066
BibTeX
@article{Ebode2026,
author = {Ebode, Dario and Truong, France and Halimi, Caroline and Dupont, Axelle and Gounant, Valerie and Faivre, Sandrine and Hourseau, Muriel and Barry, Béatrix and Brenet, Esteban and Evrard, Diane},
title = {Simultaneous Head and Neck and Lung Cancers: Implications and Therapeutic Management Timing},
journal = {Clinical Otolaryngology},
year = {2026},
doi = {10.1111/coa.70066}
}
EUVIMED